Organization Address
3280 Bayshore Blvd
Brisbane, CA 94005-1021

Organization Phone
(415) 466-2200


Biotech and Pharmaceutical

Organization Description

InterMune is a biopharmaceutical company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. In addition to three-times-a-week Infergen® (Interferon alfacon-1), a currently marketed product indicated for the treatment of chronic hepatitis C virus (HVC) infections, InterMune has a broad and deep late-stage product portfolio addressing idiopathic pulmonary fibrosis (IPF) and HVC infections, particularly nonresponders, or those patients who do not respond to first-line therapy. The pulmonology portfolio includes Actimmune® (interferon gamma-1b) and pirfenidone. Actimmune® is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF. Pirfenidone is also being developed for the treatment of IPF. Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen® plus ribavirin, and a phase IIb trial of daily Infergen® plus Actimmune® with and without ribavirin for the treatment of HCV patients who do not respond to first-line therapy. In addition, InterMune has an early stage small molecule program targeted at the HCV protease. For additional information about InterMune and its development pipeline, please visit